Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats
- 191 Downloads
The development of erythropoiesis-stimulating agents (ESAs) with extended serum half-lives has allowed marked prolongation of the administration intervals. The level of oxidative stress is increased in chronic kidney disease, and is reportedly decreased after long-term ESA treatment. However, the effect of different dosing regimens of ESAs on oxidative stress has not been elucidated.
Five-sixths nephrectomized (NX) rats received either 0.4 μg/kg darbepoetin alfa (DA) weekly or 0.8 μg/kg DA fortnightly between weeks 4 and 10. NX animals receiving saline and a sham-operated (SHAM) group served as controls. The levels of oxidized and reduced glutathione (GSSG, GSH) were followed from blood samples drawn fortnightly.
During the follow-up, the ratios GSSG/GSH showed similar trends in both DA groups, levels being significantly lower than those in the SHAM group at weeks 8 and 10. GSSG levels were lower than the baseline throughout the study in all groups except for NX controls. The GSH levels were increased in all three NX groups (weeks 6–10) compared with both the baseline and the SHAM group
Our results suggest that the extent of oxidative stress is similar in response to different dosing regimens of DA in 5/6 NX rats when comparable hemoglobin levels are maintained. These findings remain to be confirmed in chronic kidney disease patients.
KeywordsChronic kidney disease Erythropoiesis-stimulating agent (ESA) Erythropoietin Glutathione Oxidative stress Subtotal nephrectomy
This study was supported by Hungarian National Scientific Research Grant OTKA K67895 and by a Research & Development Grant of the Hungarian Society of Nephrology. T. Csont holds a János Bolyai Research Fellowship of the Hungarian Academy of Sciences.
Conflict of interest
The authors have declared that no conflict of interest exists.
- 2.KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3):S11–145.Google Scholar
- 3.Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant. 2007;22(Suppl 4):iv19–30.Google Scholar
- 13.Drabkin DL, Austin JH. Spectrophotometric studies. II. Preparations from washed blood cells; nitric oxide hemoglobin and sulfhemoglobin. J Biol Chem. 1935;112:51–65.Google Scholar
- 21.Hempe JM, Ory-Ascani J, Hsia D. Genetic variation in mouse beta globin cysteine content modifies glutathione metabolism: implications for the use of mouse models. Exp Biol Med (Maywood). 2007;232:437–44.Google Scholar